Ainos Raises $9 Million in Growth Capital with Existing Shareholder Proceeds for scaling up the company's VELDONA and AI Nose growth initiatives Convertible note convertible at $4.5 per share placed with existing shareholder #AinosInc #AIMD #AIMDW https://lnkd.in/gbtSY9CZ
Ainos | AI + Nose
Biotechnology Research
San Diego, California 165 followers
low-dose oral #interferon #VELDONA | AI-powered point-of-care test #POCT | synthetic RNA. #Ainosinc $AIMD
About us
Ainos = AI + Nose Ainos, Inc. (Nasdaq: AIMD) develops novel point-of-care testing (POCT), low-dose VELDONA interferon therapeutics, and synthetic RNA-driven preventative medicine. The company’s products include VELDONA clinical-stage human therapeutics, VELDONA Pet Cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose technology platform. twitter: https://twitter.com/AinosInc #AinosInc
- Website
-
www.ainos.com
External link for Ainos | AI + Nose
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- San Diego, California
- Type
- Public Company
- Founded
- 1986
Locations
-
Primary
Get directions
8880 Rio San Diego Drive
Suite 800
San Diego, California 92108, US
Employees at Ainos | AI + Nose
Updates
-
We are excited about the potential for VELDONA® to improve the quality of life of many people living with HIV. Oral warts can significantly reduce a person's quality of life, causing discomfort during routine activities such as eating and talking, and affecting a person's appearance. We are optimistic that VELDONA® will serve as a valuable new option for HIV-seropositive individuals seeking relief from oral warts! #AinosInc #Veldona #HIV #orphandrugs #ODD #clinicaltrials #partnership #partnerwithus
Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA A total of 77 HIV-seropositive subjects were enrolled and evaluated between a pilot study and two Phase II clinical studies. Subjects were randomly assigned to either active treatment or placebo groups, with subjects in the active treatment groups received VELDONA® lozenges via the oral cavity three times per day for 24 weeks. The placebo subjects were given a matching placebo lozenge at the same interval. After a 24-week treatment, subjects who were administered VELDONA® lozenges experienced a reduction of over 75% in the total mucosal surface area covered by oral warts. This was in a significantly greater proportion of HIV-seropositive subjects who are infected with multiple oral warts and who are receiving combination anti-retroviral therapy. #AinosInc #Veldona #HIV #orphandrugs #ODD #clinicaltrials #AIMD https://lnkd.in/gRDkZASp
Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
accesswire.com
-
Ainos Reports Full Year 2023 Financial Results Strategic pivot towards VELDONA and AI-powered point-of-care testing to continue in 2024 Advancing VELDONA drug candidates to Phase III clinical studies Expanding market of AI Nose-powered VOC-sensing technology with strategic partners NISD and Inabata https://lnkd.in/gNBrDJ8P #AinosInc
-
Thank you for seeing our presentation at the Small Cap Growth Virtual Investor Conference. Replay is available on https://lnkd.in/g5Dmeyhr #AinosInc #AIMD
Events & Presentations
ir.ainos.com
-
Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms https://lnkd.in/guYCxENX #AinosInc #VELDONA #clinicaltrial #FDA
Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms
accesswire.com
-
Ainos, Inc. will present live at the Small-Cap Growth Virtual Investor Conference, hosted by https://lnkd.in/e9k8BwT, on February 7, 2024. DATE : February 7 th , 2024 TIME: Wednesday, February 7 th , 2024 at 9:30AM ET LINK: https://bit.ly/496OeL9 Available for 1x1 meetings: February 7, 2024, 10AM-12PM ET Ainos = AI + Nose #AinosInc
Virtual Investor Conferences | Virtual Investor Conferences
virtualinvestorconferences.com
-
培多益細胞素 輕盈新包裝升級推出 冬天好冷不想動，只想窩在家裡吃東西。但是你知道嗎? 👉 美國寵物食品協會(PFI) 2017的調查中指出，台灣有60.6% 的寵物有減肥空間，其中更有29.5% 的貓咪體脂肪達36% 以上。 👈 毛孩肥胖問題不容忽視，培多益細胞素輕盈幫助毛孩體重管理! 👏 添加日本生產Fibersol®-2專利品牌的玉米膳食纖維，能幫助腸胃蠕動，增強飽足感，維持體重。 👏 添加牛磺酸，能維持身體正常代謝。 👏 提供毛孩全方位的保護力，讓毛孩陪你多益點 🐱 🐶 #培多益 #細胞素 #AinosInc #VeldonaPet #Cytoprotein #petcare
-